What Changed at Lunit SCOPE

Every material change AI Health Index has tracked at Lunit SCOPE: new modules, model and architecture updates, clinical evidence, regulatory status, security certifications, and integration depth. Each entry states what changed, cites its source, and carries our read on what it means for a buyer. The graded assessment of this vendor across all fifteen capability axes sits on its index profile.

Funding rounds, valuations, and awards are not product changes and are not logged here. Acquisitions appear only where there is direct product impact.

Follow this change log by RSS

Free for your reader, newsletter or automation tool. One feed covers the whole index, and every category has its own.

All feeds and terms

Impact

Type

1 entry

Showing changes for Lunit SCOPE only.Show the full log

October 2026

L

Lunit SCOPE

Oct 20, 2026

MediumVerified

Clinical evidence

Lunit presented five ESMO 2026 posters using Lunit SCOPE. In 993 resected lung cancers, SCOPE PD-L1 agreed with the pathologist's tumor proportion score 73 percent of the time, and 204 of the 211 disagreements fell in the 1 to 10 percent band. In 181 pancreatic cancer patients, SCOPE IO linked a higher tumor to stroma ratio with worse progression free survival, except in KRAS G12D tumors, where the link reversed.

Our read

The PD-L1 result shows exactly where the AI and pathologists part ways, which is the band a lab would want a second read on. All SCOPE products remain research use only.

Related axis: Clinical and Operational EvidenceVendor announcementView source

What has changed at Lunit SCOPE recently?

The most recent change AI Health Index logged at Lunit SCOPE is dated Oct 20, 2026. Lunit presented five ESMO 2026 posters using Lunit SCOPE.